MedTrace Logo

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

NCT06058988 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-23

No results posted yet for this study

Summary

The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

Conditions

Interventions

DRUG

Trastuzumab deruxtecan

All participants will receive T-DXd prior to indicated brain tumor resection/biopsy

Sponsors & Collaborators

Principal Investigators

  • Nelson Moss, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-22
Primary Completion
2027-09-22
Completion
2027-09-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06058988 on ClinicalTrials.gov